Daiwa upgraded AbbVie (ABBV) to Outperform from Neutral with a $214 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie’s Promising Phase 3 Study on Atogepant for Menstrual Migraine Prevention
- AbbVie’s Ubrogepant Study: A New Hope for Menstrual Migraine Relief
- AbbVie and Genmab’s Promising Update on B-Cell Lymphoma Treatment Study
- AbbVie and Genmab’s Promising Phase 3 Study for DLBCL Treatment
- Pfizer and AbbVie Collaborate on Promising Pediatric Antibiotic Study